Mirai Bio Inc. is revolutionizing the field of genetic medicine by serving as a comprehensive solutions provider for genetic medicine development, focusing on ML-enabled nucleic acid design, delivery, and manufacturing. Mirai's proprietary library of ionizable lipids includes ML-inspired components that demonstrate higher in vivo potency than leading commercial options for liver, with translation to non-human primates. By leveraging novel in-house barcoding methods, Mirai can rapidly assess multiple lipid nanoparticles (LNPs), reducing time and costs. The company’s innovative approach also includes a modular targeting LNP platform, facilitating selective extrahepatic delivery to novel tissues utilizing conjugation capabilities. The company’s unique open-platform partnership model applies Mirai’s expertise across diverse therapeutic approaches and modalities, supporting drug development of the most innovative cargos.